Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 3, 2010, Pages 1111-1116

  Crandon, Jared L ^a   Bulik, Catharine C ^a   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFEPIME; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; CALCULATION; CONTROLLED STUDY; DRUG EXPOSURE; EPSILOMETER TEST; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PHARMACODYNAMICS; PNEUMONIA; POPULATION MODEL; PREDICTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REGRESSION ANALYSIS; RISK; SKIN INFECTION; SKIN STRUCTURE; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

EID: 77149170333     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01183-09     Document Type: Article

References (26)

1. American Thoracic Society and Infectious Diseases Society of America. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171:388-416.
2. Bhat, S. V., A. Y. Peleg, T. P. Lodise, Jr., K. A. Shutt, B. Capitano, B. A. Potoski, and D. L. Paterson. 2007. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob. Agents Chemother. 51:4390-4395.
3. Charlson, M. E., P. Pompei, K. L. Ales, and C. R. MacKenzie. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40:373-383.
4. Clinical and Laboratory Standards Institute. 2008. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. CLSI publication M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
6. Crandon, J. L., J. L. Kuti, R. N. Jones, and D. P. Nicolau. 2009. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance. Ann. Pharmacother. 43:220-227.
7. Defife, R., M. H. Scheetz, J. M. Feinglass, M. J. Postelnick, and K. K. Scarsi. 2009. Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin. Antimicrob. Agents Chemother. 53:1074-1079.
8. DeRyke, C. A., J. L. Kuti, and D. P. Nicolau. 2007. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagn. Microbiol. Infect. Dis. 58:337-344.
9. Hankin, A., and W. W. Everett. 2007. Are antibiotics necessary after incision and drainage of a cutaneous abscess? Ann. Emerg. Med. 50:49-51.
10. Horan, T. C., M. Andrus, and M. A. Dudeck. 2008. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am. J. Infect. Control 36:309-332.
11. Jones, R. N., J. T. Kirby, and P. R. Rhomberg. 2008. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagn. Microbiol. Infect. Dis. 61:203-213.
12. Knaus, W. A., E. A. Draper, D. P. Wagner, and J. E. Zimmerman. 1985. APACHE II: a severity of disease classification system. Crit. Care Med. 13:818-829.
13. Lee, S. Y., J. L. Kuti, and D. P. Nicolau. 2007. Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections. J. Infect. 54:463-468.
14. Lipman, J., S. C. Wallis, and C. Rickard. 1999. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob. Agents Chemother. 43:2559-2561.
15. Luna, C. M., D. Blanzaco, M. S. Niederman, W. Matarucco, N. C. Baredes, P. Desmery, F. Palizas, G. Menga, F. Rios, and C. Apezteguia. 2003. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit. Care Med. 31:676-682.
16. Mandell, L. A., R. G. Wunderink, A. Anzueto, J. G. Bartlett, G. D. Campbell, N. C. Dean, S. F. Dowell, T. M. File, Jr., D. M. Musher, M. S. Niederman, A. Torres, and C. G. Whitney. 2007. Infectious Diseases Society of America/ American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2): S27-S72.
17. McKinnon, P. S., J. A. Paladino, and J. J. Schentag. 2008. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int. J. Antimicrob. Agents 31:345-351.
18. Nicasio, A. M., R. E. Ariano, S. A. Zelenitsky, A. Kim, J. L. Crandon, J. L. Kuti, and D. P. Nicolau. 2009. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilatorassociated pneumonia. Antimicrob. Agents Chemother. 53:1476-1481.
19. Roos, J. F., J. Bulitta, J. Lipman, and C. M. Kirkpatrick. 2006. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J. Antimicrob. Chemother. 58:987-993.
20. Solomkin, J. S., J. E. Mazuski, E. J. Baron, R. G. Sawyer, A. B. Nathens, J. T. DiPiro, T. Buchman, E. P. Dellinger, J. Jernigan, S. Gorbach, A. W. Chow, and J. Bartlett. 2003. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin. Infect. Dis. 37:997-1005.
21. Stevens, D. L., A. L. Bisno, H. F. Chambers, E. D. Everett, P. Dellinger, E. J. Goldstein, S. L. Gorbach, J. V. Hirschmann, E. L. Kaplan, J. G. Montoya, and J. C. Wade. 2005. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41:1373-1406.
22. Tam, V. H., P. S. McKinnon, R. L. Akins, G. L. Drusano, and M. J. Rybak. 2003. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob. Agents Chemother. 47:1853-1861.
23. Tam, V. H., P. S. McKinnon, R. L. Akins, M. J. Rybak, and G. L. Drusano. 2002. Pharmacodynamics of cefepime in patients with Gram-negative infections. J. Antimicrob. Chemother. 50:425-428.
24. Turnidge, J. D. 1998. The pharmacodynamics of beta-lactams. Clin. Infect. Dis. 27:10-22.
25. Yahav, D., M. Paul, A. Fraser, N. Sarid, and L. Leibovici. 2007. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect. Dis. 7:338-348.
26. Zanetti, G., F. Bally, G. Greub, J. Garbino, T. Kinge, D. Lew, J. A. Romand, J. Bille, D. Aymon, L. Stratchounski, L. Krawczyk, E. Rubinstein, M. D. Schaller, R. Chiolero, M. P. Glauser, and A. Cometta. 2003. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob. Agents Chemother. 47:3442-3447.